{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:49:32Z","timestamp":1790808572567,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Justus-Liebig-Universit\u00e4t Gie\u00dfen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patient registries are valuable tools for epidemiological research, especially for rare diseases, and a high level of data quality is essential but not always demonstrated. Although crucial, the quality management process in patient registries rarely includes data validation. The European Cystic Fibrosis Society Patient Registry (ECFSPR) collects clinical data about people with cystic fibrosis (pwCF) in Europe (as defined by the World Health Organisation (WHO) European region). This on-site data validation project was conducted by the ECFSPR to assess feasibility of the project, data accuracy and identify areas for improvement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>From November 2018 to April 2024 the ECFSPR visited centres to validate data on-site, assessing the accuracy and validity of source data for key variables related to demographics, diagnosis, organ transplant and annual disease progression. We compared data submitted to ECFSPR with medical health records (MHR) at participating centres; standardised variable definitions are used for the ECFSPR data. Accuracy (incl. validity) was expressed as the percentage of validated data points that match the MHR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We validated source data on-site in 34 of 40 (85%) participating countries and 133 of 397 (34%) centres, for 4024 pwCF (7.5% of the ECFSPR 2021 dataset). Accuracy was high for demographic data (month and year of birth, sex), transplant (&gt;\u200999%) and annual clinical data on disease progression (selected infections, medication, complications; &gt;94%). Accuracy for genetic information was 96.6% (where the original genotyping laboratory report was available which was for 85% of all pwCF). Anthropometric measurements and lung function data showed lower accuracy (87\u201388% of the validated data; this was primarily due to non-adherence to the parameters for selection of the encounter for annual lung function assessment. Data for liver disease were also comparatively less accurate (92%); this may reflect diagnostic heterogeneity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The ECFSPR on-site data validation project demonstrated its feasibility and confirmed the high accuracy of data for critical variables while also revealing specific areas for targeted quality improvement efforts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial number<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-025-04153-w","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T02:44:30Z","timestamp":1764643470000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Data accuracy in the European Cystic Fibrosis Society Patient Registry: results of an on-site data validation project"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7146-6997","authenticated-orcid":false,"given":"Naehrlich","family":"Lutz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fox","family":"Alice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krasnyk","family":"Marko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wollscheid","family":"Nadine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia Lorca","family":"Mayor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zolin","family":"Anna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasad","family":"Vibha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"ECFS Patient Registry Steering Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,2]]},"reference":[{"key":"4153_CR1","unstructured":"European Medicine Agency. Patient Registry Initiative- Strategy and Mandate of the Cross-Committee Task Force. 2017 06.01.2025]; Available from: https:\/\/www.ema.europa.eu\/en\/documents\/other\/patient-registry-initiative-strategy-and-mandate-cross-committee-task-force_en.pdf"},{"key":"4153_CR2","unstructured":"U.S. Food and Drug Administration FDA (Real-World Data: Assessing Registries to Support Regulatory Decision-Making for Drug and Biological Products - Guidance for Industry. 2023 06.01.2025]; Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/real-world-data-assessing-registries-support-regulatory-decision-making-drug-and-biological-products"},{"key":"4153_CR3","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/978-3-319-67144-4_8","volume":"1031","author":"Y Kodra","year":"2017","unstructured":"Kodra Y, et al. Data quality in rare diseases registries. Adv Exp Med Biol. 2017;1031:149\u201364.","journal-title":"Adv Exp Med Biol"},{"issue":"6","key":"4153_CR4","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1002\/ppul.26954","volume":"59","author":"J Guo","year":"2024","unstructured":"Guo J, King I, Hill A. International disparities in diagnosis and treatment access for cystic fibrosis. Pediatr Pulmonol. 2024;59(6):1622\u201330.","journal-title":"Pediatr Pulmonol"},{"key":"4153_CR5","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/1750-1172-9-81","volume":"9","author":"L Viviani","year":"2014","unstructured":"Viviani L, et al. The European cystic fibrosis society patient registry: valuable lessons learned on how to sustain a disease registry. Orphanet J Rare Dis. 2014;9:81.","journal-title":"Orphanet J Rare Dis"},{"key":"4153_CR6","unstructured":"Zolin A et al. ECFSPR Annual Report 2021, European Cystic Fibrosis Society, Editor. 2022."},{"key":"4153_CR7","unstructured":"Agency EM. Qualification Opinion on The European Cystic Fibrosis Society Patient Registry (ECFSPR) and CF Pharmaco- epidemiology Studies. 2018 05.01.2024]; Available from: https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/qualification-opinion-european-cystic-fibrosis-society-patient-registry-ecfspr-cf-pharmaco_en.pdf"},{"key":"4153_CR8","doi-asserted-by":"crossref","unstructured":"Ali SR et al. The quality evaluation of rare disease registries-an assessment of the essential features of a disease registry. Int J Environ Res Public Health, 2021. 18(22).","DOI":"10.3390\/ijerph182211968"},{"key":"4153_CR9","unstructured":"Kodra Y et al. Recommendations for improving the quality of rare disease registries. Int J Environ Res Public Health, 2018. 15(8)."},{"issue":"7","key":"4153_CR10","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1513\/AnnalsATS.201511-781OC","volume":"13","author":"EA Knapp","year":"2016","unstructured":"Knapp EA, et al. The cystic fibrosis foundation patient registry. Design and methods of a National observational disease registry. Ann Am Thorac Soc. 2016;13(7):1173\u20139.","journal-title":"Ann Am Thorac Soc"},{"issue":"Suppl 1","key":"4153_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13023-017-0750-x","volume":"13","author":"N Pellen","year":"2018","unstructured":"Pellen N, et al. Lessons from the on-site quality audit of data transmitted to the French cystic fibrosis registry. Orphanet J Rare Dis. 2018;13(Suppl 1):9.","journal-title":"Orphanet J Rare Dis"},{"key":"4153_CR12","doi-asserted-by":"publisher","first-page":"S80","DOI":"10.1016\/S1569-1993(19)30376-5","volume":"18","author":"E Gunn","year":"2019","unstructured":"Gunn E, et al. P082 UK cystic fibrosis registry data validation programme. J Cyst Fibros. 2019;18:S80\u20131.","journal-title":"J Cyst Fibros"},{"issue":"3","key":"4153_CR13","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.jcf.2023.08.015","volume":"23","author":"L Wolf","year":"2024","unstructured":"Wolf L, et al. Data accuracy, consistency and completeness of the National Swiss cystic fibrosis patient registry: lessons from an ECFSPR data quality project. J Cyst Fibros. 2024;23(3):506\u201311.","journal-title":"J Cyst Fibros"},{"issue":"5","key":"4153_CR14","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1016\/j.jcf.2016.03.003","volume":"15","author":"CL Hartley","year":"2016","unstructured":"Hartley CL, et al. Challenge for a new era-importance of ensuring accuracy of genotype in cystic fibrosis registries. J Cyst Fibros. 2016;15(5):e50\u20131.","journal-title":"J Cyst Fibros"},{"issue":"11","key":"4153_CR15","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/S2213-2600(24)00208-X","volume":"12","author":"P Burgel","year":"2024","unstructured":"Burgel P, et al. The expanded French compassionate programme for elexacaftor-tezacaftor-ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study. Lancet Respir Med. 2024;12(11):888\u2013900.","journal-title":"Lancet Respir Med"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04153-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-04153-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04153-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T11:31:11Z","timestamp":1766057471000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-025-04153-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4153"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-04153-w","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,2]]},"assertion":[{"value":"28 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for ECFSPR participation and consent to participate were granted by each participating centre.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"LN and VB receive institutional funding from the ECFS for Pharmacovigilance studies. AF is employed by the ECFS. NW, MK, SLM receive institutional funding for performing on-site data validations from the ECFS. AZ receive institutional funding for data management from the ECFS.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"622"}}